{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:18:43Z","timestamp":1770722323315,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201300017I"],"award-info":[{"award-number":["HHSN272201300017I"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.conctc.2021.100851","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T07:31:32Z","timestamp":1634283092000},"page":"100851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever)"],"prefix":"10.1016","volume":"24","author":[{"given":"Julia A.","family":"Messina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen K.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7882-1883","authenticated-orcid":false,"given":"John","family":"Galgiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan T.","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung K.","family":"Htoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1091-348X","authenticated-orcid":false,"given":"Arash","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Royce H.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneesh T.","family":"Narang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariba M.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Ewell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Catanzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"George R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil M.","family":"Ampel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Perfect","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Naggie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.conctc.2021.100851_bib1","first-page":"621","article-title":"Coccidioidomycosis","volume":"20","author":"Anstead","year":"2006","journal-title":"Infect. Dis. Clin."},{"issue":"6","key":"10.1016\/j.conctc.2021.100851_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3201\/eid2006.131842","article-title":"Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis","volume":"20","author":"Blair","year":"2014","journal-title":"Emerg. Infect. Dis."},{"issue":"1","key":"10.1016\/j.conctc.2021.100851_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1128\/CVI.00531-12","article-title":"Clinical specificity of the enzyme immunoassay test for coccidioidomycosis varies according to the reason for its performance","volume":"20","author":"Blair","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"issue":"3","key":"10.1016\/j.conctc.2021.100851_bib4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0002-9343(99)80371-4","article-title":"Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group","volume":"98","author":"Catanzaro","year":"1995","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.conctc.2021.100851_bib5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/jac\/dky501","article-title":"Tolerability of long-term fluconazole therapy","volume":"74","author":"Davis","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"issue":"9","key":"10.1016\/j.conctc.2021.100851_bib6","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3201\/eid2509.190023","article-title":"Delays in coccidioidomycosis diagnosis and associated healthcare utilization, Tucson, Arizona, USA","volume":"25","author":"Donovan","year":"2019","journal-title":"Emerg. Infect. Dis."},{"issue":"6","key":"10.1016\/j.conctc.2021.100851_bib7","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 infectious diseases society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.conctc.2021.100851_bib8","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1093\/cid\/ciz933","article-title":"Treatment for early, uncomplicated coccidioidomycosis: what is success?","volume":"70","author":"Galgiani","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.conctc.2021.100851_bib9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.7326\/0003-4819-133-9-200011070-00009","article-title":"Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group","volume":"133","author":"Galgiani","year":"2000","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"10.1016\/j.conctc.2021.100851_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/0002-9343(90)90339-F","article-title":"Itraconazole treatment of coccidioidomycosis. NAIAD mycoses study group","volume":"89","author":"Graybill","year":"1990","journal-title":"Am. J. Med."},{"issue":"10","key":"10.1016\/j.conctc.2021.100851_bib11","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","article-title":"The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus","volume":"46","author":"Krupp","year":"1989","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.conctc.2021.100851_bib12","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1128\/JCM.01843-09","article-title":"False-positive IgM serology in coccidioidomycosis","volume":"48","author":"Kuberski","year":"2010","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"10.1016\/j.conctc.2021.100851_bib13","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1378\/chest.124.6.2182","article-title":"The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation","volume":"124","author":"Leidy","year":"2003","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.conctc.2021.100851_bib14","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1128\/CVI.00375-15","article-title":"Evaluation of the specificity of two enzyme immunoassays for coccidioidomycosis by using sera from a region of endemicity and a region of nonendemicity","volume":"22","author":"Lindsley","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.conctc.2021.100851_bib15","series-title":"Valley Fever 2017 Annual Report","author":"Services","year":"2017"},{"issue":"11","key":"10.1016\/j.conctc.2021.100851_bib16","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3201\/eid1611.100475","article-title":"Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007-2008","volume":"16","author":"Tsang","year":"2010","journal-title":"Emerg. Infect. Dis."}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865421001514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865421001514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:07:11Z","timestamp":1762520831000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865421001514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":16,"alternative-id":["S2451865421001514"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2021.100851","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized, double-blind, placebo-controlled clinical trial of fluconazole as early empiric treatment of coccidioidomycosis pneumonia (Valley Fever) in adults presenting with community-acquired pneumonia in endemic areas (FLEET-Valley Fever)","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2021.100851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100851"}}